Lyme disease tests are highly accurate in later stages of infection but significantly less reliable in the first few weeks after a tick bite. The standard two-tier blood test catches 97% to 100% of patients with Lyme arthritis or late neurological symptoms, but only about 50% of patients tested during the earliest stage, when the bullseye rash is still present. That gap matters because early detection is when treatment works best.
How the Standard Test Works
The CDC-recommended approach uses two blood tests in sequence. The first is a screening test (an immunoassay) that checks whether your blood contains antibodies against the Lyme bacterium. If that screening comes back positive or borderline, a second, more specific test called a Western blot is run on the same blood sample to confirm the result. This two-step process exists because the screening test alone can flag antibodies from other conditions, leading to false positives.
Both tests measure your immune system’s response to the infection, not the bacterium itself. That’s the core limitation: your body needs time to build detectable antibodies, and that delay creates a window where the tests simply can’t find anything yet.
The Early Detection Problem
After a tick bite, your body needs several days to a few weeks before it produces enough antibodies to show up on a blood test. IgM antibodies appear first, but the broader IgG antibody response that the test relies on takes one to two months of untreated infection to fully develop.
This means that if you’re tested while you still have the characteristic bullseye rash (called erythema migrans), which typically appears within days to a few weeks, the test will miss roughly half of true infections. A large European meta-analysis found sensitivity of just 50% at this stage. For early neurological complications like facial paralysis or meningitis, accuracy improves to around 80% to 88%, but that still means one or two out of every ten cases go undetected.
This is why doctors in Lyme-endemic areas often skip the blood test entirely when a patient has the classic rash and a plausible tick exposure. They’ll start antibiotic treatment based on symptoms alone, because waiting for a positive test could mean losing valuable treatment time.
Accuracy in Later Stages
The picture changes dramatically once infection has been present for several weeks or longer. Patients with Lyme arthritis or late-stage neurological disease test positive 97% to 100% of the time. At this point, the immune system has had plenty of time to mount a robust antibody response, and the two-tier test becomes very reliable.
Specificity, the test’s ability to correctly identify people who don’t have Lyme disease, is consistently strong at all stages. In diagnostic reference labs, specificity sits at 99% or higher. That means false positives are rare when the full two-tier protocol is followed correctly.
What Causes False Positives
While rare with the complete two-tier process, false positives do happen. Certain infections and conditions produce antibodies that look similar enough to Lyme antibodies to trigger the screening test. The most common culprits are syphilis, relapsing fever (caused by a closely related bacterium), Epstein-Barr virus (the virus behind mono), and rheumatoid arthritis.
The second-tier Western blot exists specifically to catch these. It requires a very specific pattern of antibody bands to count as positive: at least five out of ten designated protein bands for the IgG version. That strict threshold is what keeps the false positive rate so low. If only the screening test is run without confirmation, specificity drops noticeably, to as low as 92% in some studies.
The Western Blot’s Scoring System
The Western blot separates proteins by size and checks which ones your antibodies react to. For the IgG blot, which is used when symptoms have been present for more than 30 days, the CDC requires reactivity against at least five of ten specific protein bands. Meeting four out of ten counts as negative, even if your symptoms are consistent with Lyme disease. This all-or-nothing threshold improves specificity but can occasionally miss true infections, particularly in patients with an atypical or muted immune response.
For symptoms present less than 30 days, an IgM blot is also considered, but it has a narrower set of bands and is more prone to false positives. This is why IgM results alone in patients with long-standing symptoms are generally not considered reliable.
Newer Testing Approaches
A modified version of the two-tier protocol replaces the Western blot with a second, different immunoassay. Instead of running a screening test followed by a blot, this approach uses two immunoassays back to back. Studies comparing the two strategies found that the modified approach achieved 100% sensitivity for Lyme arthritis and neuroborreliosis, compared to 90% to 97% for the traditional protocol. Specificity remained comparable between the two methods.
Rapid point-of-care tests are also in development. One paper-based platform using synthetic peptides and machine learning achieved 95.5% sensitivity and 100% specificity in blinded testing against CDC reference samples. It correctly distinguished Lyme disease from conditions that mimic it. These tests aren’t yet widely available, but they represent a shift toward faster, decentralized diagnosis that could eventually replace the need for centralized lab processing.
What This Means in Practice
If you’re tested within the first couple of weeks after a tick bite, a negative result doesn’t rule out Lyme disease. Your body may not have produced enough antibodies yet. If your doctor suspects Lyme based on your symptoms, exposure history, and the presence of a rash, treatment typically starts regardless of test results. You can be retested a few weeks later if the initial result was negative and symptoms persist.
If you’re tested after a month or more of symptoms, particularly joint swelling or neurological issues, the two-tier test is highly reliable. A positive result at that stage is very likely a true positive, and a negative result strongly suggests the symptoms have a different cause. The test works best when it’s used in the right clinical context: not as a screening tool for vague symptoms, but as confirmation when Lyme disease is already a reasonable suspicion based on your history and where you live.